Yasin Akbari

The Inflation Reduction Act, signed into law in August 2022, enacted significant changes in the way the government treats certain prescription drugs under the Medicare program. Prior to the IRA, Congress left Medicare drug pricing to the drug manufacturers, pharmacies, and insurance plan sponsors to negotiate and expressly prohibited the government from “interfering” in those private price negotiations under the so-called “Non-Interference Clause” of the Medicare Modernization Act of 2003.

The Inflation Reduction Act, signed into law in August 2022, enacted significant changes in the way the government treats certain prescription drugs under the Medicare program. Prior to the IRA, Congress left Medicare drug pricing to the drug manufacturers, pharmacies, and insurance plan sponsors to negotiate and expressly prohibited the government from “interfering” in those private price negotiations under the so-called “Non-Interference Clause” of the Medicare Modernization Act of 2003.

The Life Sciences team advised Anagram Therapeutics (Anagram) on a $250 million investment from Blackstone Life Sciences (BXLS). The investment will help fund the further development, approval, and launch of Anagram’s ANG003, a novel orally delivered recombinant enzyme replacement therapy that has demonstrated positive clinical data in people with exocrine pancreatic insufficiency (EPI) due to CF. This community currently faces a highly disruptive pill burden, taking up to 40 pills daily.